Organon & Co.
General ticker "OGN" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $3.1B (TTM average)
Organon & Co. does not follow the US Stock Market performance with the rate: -12.7%.
Estimated limits based on current volatility of 3.4%: low 7.20$, high 7.71$
Factors to consider:
- Company pays dividends (quarterly): last record date 2025-08-15, amount 0.02$ (Y1.12%)
- Total employees count: 10000 (0.0%) as of 2024
- China accounted for 13.2% of revenue in the fiscal year ended 2024-12-31
- US accounted for 10.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Geopolitical risks, Market competition, Acquisition/divestiture risks, Regulatory and compliance
- Current price 41.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.14$, 21.61$]
- 2025-12-31 to 2026-12-31 estimated range: [14.24$, 24.53$]
Financial Metrics affecting the OGN estimates:
- Positive: with PPE of 3.6 at the end of fiscal year the price was very low
- Positive: Operating profit margin, % of 23.21 > 18.64
- Positive: Operating cash flow per share per price, % of 24.81 > 13.24
- Negative: Shareholder equity ratio, % of 3.60 <= 18.93
- Positive: Inventory ratio change, % of -0.25 <= 0
- Negative: Industry operating cash flow per share per price (median), % of 8.11 <= 10.33
Short-term OGN quotes
Long-term OGN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $6,174.00MM | $6,263.00MM | $6,403.00MM |
| Operating Expenses | $4,469.00MM | $4,936.00MM | $4,917.00MM |
| Operating Income | $1,705.00MM | $1,327.00MM | $1,486.00MM |
| Non-Operating Income | $-583.00MM | $-654.00MM | $-679.00MM |
| Interest Expense | $422.00MM | $527.00MM | $520.00MM |
| R&D Expense | $471.00MM | $528.00MM | $469.00MM |
| Income(Loss) | $1,122.00MM | $673.00MM | $807.00MM |
| Taxes | $205.00MM | $-350.00MM | $-57.00MM |
| Profit(Loss)* | $917.00MM | $1,023.00MM | $864.00MM |
| Stockholders Equity | $-892.00MM | $-70.00MM | $472.00MM |
| Inventory | $1,003.00MM | $1,315.00MM | $1,321.00MM |
| Assets | $10,955.00MM | $12,058.00MM | $13,101.00MM |
| Operating Cash Flow | $858.00MM | $799.00MM | $939.00MM |
| Capital expenditure | $427.00MM | $261.00MM | $351.00MM |
| Investing Cash Flow | $-420.00MM | $-260.00MM | $-513.00MM |
| Financing Cash Flow | $-433.00MM | $-569.00MM | $-368.00MM |
| Earnings Per Share** | $3.61 | $4.01 | $3.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.